120 related articles for article (PubMed ID: 24789268)
1. Development of a dendritic cell-targeting lipopeptide as an immunoadjuvant that inhibits tumor growth without inducing local inflammation.
Akazawa T; Ohashi T; Nakajima H; Nishizawa Y; Kodama K; Sugiura K; Inaba T; Inoue N
Int J Cancer; 2014 Dec; 135(12):2847-56. PubMed ID: 24789268
[TBL] [Abstract][Full Text] [Related]
2. Development of a vaccine based on bacteria-mimicking tumor cells coated with novel engineered toll-like receptor 2 ligands.
Akazawa T; Ohashi T; Wijewardana V; Sugiura K; Inoue N
Cancer Sci; 2018 May; 109(5):1319-1329. PubMed ID: 29575556
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant engineering for cancer immunotherapy: Development of a synthetic TLR2 ligand with increased cell adhesion.
Akazawa T; Inoue N; Shime H; Kodama K; Matsumoto M; Seya T
Cancer Sci; 2010 Jul; 101(7):1596-603. PubMed ID: 20507323
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
5. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
6. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens.
Prajeeth CK; Jirmo AC; Krishnaswamy JK; Ebensen T; Guzman CA; Weiss S; Constabel H; Schmidt RE; Behrens GM
Eur J Immunol; 2010 May; 40(5):1272-83. PubMed ID: 20213735
[TBL] [Abstract][Full Text] [Related]
7. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
8. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
9. Dendritic Cell Sensing of Hydrophobic Di- and Triacylated Lipopeptides Self-Assembled within Synthetic Virus-like Particles.
Sharma R; Ghasparian A; Robinson JA; McCullough KC
J Immunol; 2017 Jul; 199(2):734-749. PubMed ID: 28630093
[TBL] [Abstract][Full Text] [Related]
10. Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo.
Matsumoto M; Tatematsu M; Nishikawa F; Azuma M; Ishii N; Morii-Sakai A; Shime H; Seya T
Nat Commun; 2015 Feb; 6():6280. PubMed ID: 25692975
[TBL] [Abstract][Full Text] [Related]
11. Salmonella induces death of CD8alpha(+) dendritic cells but not CD11c(int)CD11b(+) inflammatory cells in vivo via MyD88 and TNFR1.
Sundquist M; Wick MJ
J Leukoc Biol; 2009 Feb; 85(2):225-34. PubMed ID: 19004989
[TBL] [Abstract][Full Text] [Related]
12. PEGylation of a TLR2-agonist-based vaccine delivery system improves antigen trafficking and the magnitude of ensuing antibody and CD8
Sekiya T; Yamagishi J; Gray JHV; Whitney PG; Martinelli A; Zeng W; Wong CY; Sugimoto C; Jackson DC; Chua BY
Biomaterials; 2017 Aug; 137():61-72. PubMed ID: 28544973
[TBL] [Abstract][Full Text] [Related]
13. Enhanced immunostimulatory activity of in silico discovered agonists of Toll-like receptor 2 (TLR2).
Murgueitio MS; Ebner S; Hörtnagl P; Rakers C; Bruckner R; Henneke P; Wolber G; Santos-Sierra S
Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt A):2680-2689. PubMed ID: 28734965
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
[TBL] [Abstract][Full Text] [Related]
15. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
16. Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression.
Verma V; Kim Y; Lee MC; Lee JT; Cho S; Park IK; Min JJ; Lee JJ; Lee SE; Rhee JH
Oncotarget; 2016 Jun; 7(26):39894-39906. PubMed ID: 27223090
[TBL] [Abstract][Full Text] [Related]
17. Geometry of a TLR2-Agonist-Based Adjuvant Can Affect the Resulting Antigen-Specific Immune Response.
Wijayadikusumah AR; Zeng W; McQuilten HA; Wong CY; Jackson DC; Chua BY
Mol Pharm; 2019 May; 16(5):2037-2047. PubMed ID: 30924661
[TBL] [Abstract][Full Text] [Related]
18. Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2.
Chua BY; Pejoski D; Turner SJ; Zeng W; Jackson DC
J Immunol; 2011 Aug; 187(4):1692-701. PubMed ID: 21742967
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route.
Lombardi V; Van Overtvelt L; Horiot S; Moussu H; Chabre H; Louise A; Balazuc AM; Mascarell L; Moingeon P
Clin Exp Allergy; 2008 Nov; 38(11):1819-29. PubMed ID: 18644025
[TBL] [Abstract][Full Text] [Related]
20. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
